Skip to main content
Premium Trial:

Request an Annual Quote

Sequitur, Procter and Gamble Pharmaceuticals to Collaborate on Target Validation Study

NEW YORK, Oct. 9 – Sequitur has entered into an agreement with Procter and Gamble Pharmaceuticals to provide the company access to its functional genomics technology, the companies announced Tuesday.

Sequitur, based in Natick, Mass., will perform biological screening and supply its proprietary antisense compounds and methods to Procter and Gamble for use in its target validation studies as part of a multi-year agreement, according to the companies. 

Financial details were not disclosed. 

“We are pleased to enter into this collaboration with Sequitur, which promises to accelerate the validation of our genomic targets across our therapeutic areas,” Gordon Hassing, vice president of R&D at Procter and Gamble Pharmaceuticals, said in a statement.

In September, Sequitur signed a multi-year agreement with Minneapolis-based Discovery Genomics to collaborate on screening antisense compounds and studying gene function in zebra fish.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.